These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 12855645)

  • 61. Epigenetic inactivation of the thyroid hormone receptor beta1 gene at 3p24.2 in lung cancer.
    Iwasaki Y; Sunaga N; Tomizawa Y; Imai H; Iijima H; Yanagitani N; Horiguchi K; Yamada M; Mori M
    Ann Surg Oncol; 2010 Aug; 17(8):2222-8. PubMed ID: 20155399
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.
    Yue W; Dacic S; Sun Q; Landreneau R; Guo M; Zhou W; Siegfried JM; Yu J; Zhang L
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4336-44. PubMed ID: 17671114
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Aberrant methylation of ADAMTS1 in non-small cell lung cancer.
    Choi JE; Kim DS; Kim EJ; Chae MH; Cha SI; Kim CH; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2008 Dec; 187(2):80-4. PubMed ID: 19027488
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.
    Burbee DG; Forgacs E; Zöchbauer-Müller S; Shivakumar L; Fong K; Gao B; Randle D; Kondo M; Virmani A; Bader S; Sekido Y; Latif F; Milchgrub S; Toyooka S; Gazdar AF; Lerman MI; Zabarovsky E; White M; Minna JD
    J Natl Cancer Inst; 2001 May; 93(9):691-9. PubMed ID: 11333291
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
    Shames DS; Girard L; Gao B; Sato M; Lewis CM; Shivapurkar N; Jiang A; Perou CM; Kim YH; Pollack JR; Fong KM; Lam CL; Wong M; Shyr Y; Nanda R; Olopade OI; Gerald W; Euhus DM; Shay JW; Gazdar AF; Minna JD
    PLoS Med; 2006 Dec; 3(12):e486. PubMed ID: 17194187
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hypermethylation of the p16 (Ink4a) promoter in B6C3F1 mouse primary lung adenocarcinomas and mouse lung cell lines.
    Patel AC; Anna CH; Foley JF; Stockton PS; Tyson FL; Barrett JC; Devereux TR
    Carcinogenesis; 2000 Sep; 21(9):1691-700. PubMed ID: 10964101
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation.
    Zöchbauer-Müller S; Fong KM; Geradts J; Xu X; Seidl S; End-Pfützenreuter A; Lang G; Heller G; Zielinski CC; Gazdar AF; Minna JD
    Oncogene; 2005 Sep; 24(41):6249-55. PubMed ID: 15940253
    [TBL] [Abstract][Full Text] [Related]  

  • 68. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.
    Endoh H; Yatabe Y; Shimizu S; Tajima K; Kuwano H; Takahashi T; Mitsudomi T
    Int J Cancer; 2003 Aug; 106(1):45-51. PubMed ID: 12794755
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Methylation of specific CpG sites in the promoter region could significantly down-regulate p16(INK4a) expression in gastric adenocarcinoma.
    Song SH; Jong HS; Choi HH; Kang SH; Ryu MH; Kim NK; Kim WH; Bang YJ
    Int J Cancer; 2000 Jul; 87(2):236-40. PubMed ID: 10861481
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.
    Izumi H; Inoue J; Yokoi S; Hosoda H; Shibata T; Sunamori M; Hirohashi S; Inazawa J; Imoto I
    Hum Mol Genet; 2005 Apr; 14(8):997-1007. PubMed ID: 15746151
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Expression of placental growth factor gene in lung cancer.
    Woo IS; Park MJ; Byun JH; Hong YS; Lee KS; Park YS; Lee JA; Park YI; Ahn HK
    Tumour Biol; 2004; 25(1-2):1-6. PubMed ID: 15192305
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers.
    Dallol A; Forgacs E; Martinez A; Sekido Y; Walker R; Kishida T; Rabbitts P; Maher ER; Minna JD; Latif F
    Oncogene; 2002 May; 21(19):3020-8. PubMed ID: 12082532
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer.
    Tanaka N; Toyooka S; Soh J; Kubo T; Yamamoto H; Maki Y; Muraoka T; Shien K; Furukawa M; Ueno T; Asano H; Tsukuda K; Aoe K; Miyoshi S
    Lung Cancer; 2012 Apr; 76(1):32-8. PubMed ID: 22047961
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies.
    Shigematsu H; Suzuki M; Takahashi T; Miyajima K; Toyooka S; Shivapurkar N; Tomlinson GE; Mastrangelo D; Pass HI; Brambilla E; Sathyanarayana UG; Czerniak B; Fujisawa T; Shimizu N; Gazdar AF
    Int J Cancer; 2005 Feb; 113(4):600-4. PubMed ID: 15472908
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The CpG island promoter of the human proopiomelanocortin gene is methylated in nonexpressing normal tissue and tumors and represses expression.
    Newell-Price J; King P; Clark AJ
    Mol Endocrinol; 2001 Feb; 15(2):338-48. PubMed ID: 11158338
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer.
    Yu J; Bulk E; Ji P; Hascher A; Tang M; Metzger R; Marra A; Serve H; Berdel WE; Wiewroth R; Koschmieder S; Müller-Tidow C
    Clin Cancer Res; 2010 Apr; 16(8):2275-83. PubMed ID: 20371680
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.
    Agathanggelou A; Honorio S; Macartney DP; Martinez A; Dallol A; Rader J; Fullwood P; Chauhan A; Walker R; Shaw JA; Hosoe S; Lerman MI; Minna JD; Maher ER; Latif F
    Oncogene; 2001 Mar; 20(12):1509-18. PubMed ID: 11313894
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Defective expression of transforming growth factor beta receptor type II is associated with CpG methylated promoter in primary non-small cell lung cancer.
    Zhang HT; Chen XF; Wang MH; Wang JC; Qi QY; Zhang RM; Xu WQ; Fei QY; Wang F; Cheng QQ; Chen F; Zhu CS; Tao SH; Luo Z
    Clin Cancer Res; 2004 Apr; 10(7):2359-67. PubMed ID: 15073112
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Aberrant methylation of FBN2 in human non-small cell lung cancer.
    Chen H; Suzuki M; Nakamura Y; Ohira M; Ando S; Iida T; Nakajima T; Nakagawara A; Kimura H
    Lung Cancer; 2005 Oct; 50(1):43-9. PubMed ID: 15951052
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers.
    Wu YH; Tsai Chang JH; Cheng YW; Wu TC; Chen CY; Lee H
    Oncogene; 2007 Jul; 26(33):4761-73. PubMed ID: 17325666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.